Alzheimer’s campaigners say the progression of research has suffered a “devastating blow” after a new drug was rejected for use on the NHS in Scotland.
Donanemab delays the onset of dementia and works by targeting a cause of the disease, rather than just treating its symptoms.
The Scottish Medicines Consortium says there isn’t enough evidence to prove how well it works.
Follow STV News on WhatsApp
Scan the QR code on your mobile device for all the latest news from around the country
